Complementary assays helping to overcome challenges for identifying neuraminidase inhibitors

Future Virology

Volumn 10, Issue 2, 2015, Pages 77-88

  Richter, Martina ^a   Schumann, Lilia ^a   Walther, Elisabeth ^a   Hoffmann, Anja ^a   Braun, Heike ^a   Grienke, Ulrike ^b,c   Rollinger, Judith M ^c   Von Grafenstein, Susanne ^b   Liedl, Klaus R ^b   Kirchmair, Johannes ^d   Wutzler, Peter ^a   Sauerbrei, Andreas ^a   Schmidtke, Michaela ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF HAMBURG   (Germany)

Author keywords

assay interference; Clostridium perfringens; influenza virus; neuraminidase inhibition assay; neuraminidase inhibitors; self fluorescence; signal quenching; Streptococcus pneumoniae; Vibrio cholerae

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; KATSUMADAIN A; N ACETYL 2,3 DEHYDRO 2 DEOXYNEURAMINIC ACID; NUCLEOZIN; OSELTAMIVIR; REMAZOL; RIFAMPICIN; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANIMAL CELL; ARTICLE; BIOASSAY; CHEMOLUMINESCENCE; CLOSTRIDIUM PERFRINGENS; COMPLEMENTARY BIOASSAY; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; FLUORESCENCE ANALYSIS; HEMAGGLUTINATION; HUMAN; HUMAN CELL; INFLUENZA VIRUS; MDCK CELL LINE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; VIBRIO CHOLERAE;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM PERFRINGENS; ORTHOMYXOVIRIDAE; STREPTOCOCCUS PNEUMONIAE; VIBRIO CHOLERAE;

EID: 84923282216     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.97     Document Type: Article

References (35)

1. Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12(3), 159-166 (2002).
2. Palese P, Shaw M. Orthomyxoviridae: the viruses and their replication. In: Fileds Virology. Knipe D, Howley P (Eds). Lippincott, Williams & Wilkins, PA, USA, 1647-1689 (2007).
3. Grienke U, Schmidtke M, von Grafenstein S, Kirchmair J, Liedl KR, Rollinger JM. Influenza neuraminidase: a druggable target for natural products. Nat. Prod. Rep. 29(1), 11-36 (2012).
4. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther. 17(1 Pt B), 159-173 (2012).
5. Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Euro. Surveill. 13(5) (2008).
6. Okomo-Adhiambo M, Sleeman K, Ballenger K et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2(10), 2269-2289 (2010).
7. Cheng TJ, Weinheimer S, Tarbet EB et al. Development of oseltamivir phosphonate congeners as anti-influenza agents. J. Med. Chem. 55(20), 8657-8670 (2012).
8. Schade D, Kotthaus J, Riebling L et al. Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. J. Med. Chem. 57(3), 759-769 (2014).
9. Hsu KC, Hung HC, Horng JT et al. Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors. PLoS ONE 8(2), e56704 (2013).
10. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat. Rev. Microbiol. 12(4), 252-262 (2014).
11. Manco S, Hernon F, Yesilkaya H, Paton JC, Andrew PW, Kadioglu A. Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis. Infect. Immun. 74(7), 4014-4020 (2006).
12. Pettigrew MM, Fennie KP, York MP, Daniels J, Ghaffar F. Variation in the presence of neuraminidase genes among Streptococcus pneumoniae isolates with identical sequence types. Infect. Immun. 74(6), 3360-3365 (2006).
13. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J. Infect. Dis. 186(3), 341-350 (2002).
14. Gut H, Xu G, Taylor GL, Walsh MA. Structural basis for Streptococcus pneumoniae NanA inhibition by influenza antivirals zanamivir and oseltamivir carboxylate. J. Mol. Biol. 409(4), 496-503 (2011).
15. Bauer K, Durrwald R, Schlegel M et al. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Med. Microbiol. Immunol. 201(1), 61-72 (2012).
16. Bauer K, Richter M, Wutzler P, Schmidtke M. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006. Antiviral Res. 82(1), 34-41 (2009).
17. Hurt AC, Okomo-Adhiambo M, Gubareva LV. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods Mol. Biol. 865, 115-125 (2012).
18. Okomo-Adhiambo M, Sheu TG, Gubareva LV. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respir. Viruses 7(Suppl. 1), 44-49 (2013).
19. Wetherall NT, Trivedi T, Zeller J et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41(2), 742-750 (2003).
20. Mishin VP, Sleeman K, Levine M, Carney PJ, Stevens J, Gubareva LV. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A (H3N2) viruses. Antiviral Res. 101, 93-96 (2014).
21. Grienke U, Schmidtke M, Kirchmair J et al. Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J. Med. Chem. 53(2), 778-786 (2010).
22. Kirchmair J, Rollinger JM, Liedl KR, Seidel N, Krumbholz A, Schmidtke M. Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode. Future Med. Chem. 3(4), 437-450 (2011).
23. Lin CH, Chang TC, Das A et al. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities. Org. Biomol. Chem. 11(24), 3943-3948 (2013).
24. Chamni S, De-Eknamkul W. Recent progress and challenges in the discovery of new neuraminidase inhibitors. Expert Opin. Ther. Pat. 23(4), 409-423 (2013).
25. Kongkamnerd J, Milani A, Cattoli G et al. The quenching effect of flavonoids on 4-methylumbelliferone, a potential pitfall in fluorimetric neuraminidase inhibition assays. J. Biomol. Screen. 16(7), 755-764 (2011).
26. Duerrwald R, Schlegel M, Bauer K, Vissiennon T, Wutzler P, Schmidtke M. Efficacy of influenza vaccination and tamiflu(R) treatment-comparative studies with Eurasian Swine influenza viruses in pigs. PLoS ONE 8(4), e61597 (2013).
27. Sandbulte MR, Gao J, Straight TM, Eichelberger MC. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir. Viruses 3(5), 233-240 (2009).
28. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 54(9), 3671-3677 (2010).
29. Duwe S, Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J. Virol. Methods 153(2), 134-141 (2008).
30. Nakano V, Fontes Piazza RM, Avila-Campos MJ. A rapid assay of the sialidase activity in species of the Bacteroides fragilis group by using peanut lectin hemagglutination. Anaerobe 12(5-6), 238-241 (2006).
31. Duwe SC, Wedde M, Birkner P, Schweiger B. Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany. Antiviral Res. 89(1), 115-118 (2011).
32. Okomo-Adhiambo M, Sleeman K, Lysen C et al. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir. Viruses 7(5), 645-658 (2013).
33. Parker D, Soong G, Planet P, Brower J, Ratner AJ, Prince A. The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation. Infect. Immun. 77(9), 3722-3730 (2009).
34. McKimm-Breschkin JL, Williams J, Barrett S et al. Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J. Antimicrob. Chemother. 68(10), 2210-2221 (2013).
35. Blick TJ, Sahasrabudhe A, McDonald M et al. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 246(1), 95-103 (1998).